Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Nov 14;11(11):CD007504.
doi: 10.1002/14651858.CD007504.pub2.

Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents

Affiliations
Meta-Analysis

Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents

Georgina R Cox et al. Cochrane Database Syst Rev. .

Abstract

Background: Depressive disorders often begin during childhood or adolescence. There is a growing body of evidence supporting effective treatments during the acute phase of a depressive disorder. However, little is known about treatments for preventing relapse or recurrence of depression once an individual has achieved remission or recovery from their symptoms.

Objectives: To determine the efficacy of early interventions, including psychological and pharmacological interventions, to prevent relapse or recurrence of depressive disorders in children and adolescents.

Search methods: We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR) (to 1 June 2011). The CCDANCTR contains reports of relevant randomised controlled trials from The Cochrane Library (all years), EMBASE (1974 to date), MEDLINE (1950 to date) and PsycINFO (1967 to date). In addition we handsearched the references of all included studies and review articles.

Selection criteria: Randomised controlled trials using a psychological or pharmacological intervention, with the aim of preventing relapse or recurrence from an episode of major depressive disorder (MDD) or dysthymic disorder (DD) in children and adolescents were included. Participants were required to have been diagnosed with MDD or DD according to DSM or ICD criteria, using a standardised and validated assessment tool.

Data collection and analysis: Two review authors independently assessed all trials for inclusion in the review, extracted trial and outcome data, and assessed trial quality. Results for dichotomous outcomes are expressed as odds ratio and continuous measures as mean difference or standardised mean difference. We combined results using random-effects meta-analyses, with 95% confidence intervals. We contacted lead authors of included trials and requested additional data where possible.

Main results: Nine trials with 882 participants were included in the review. In five trials the outcome assessors were blind to the participants' intervention condition and in the remainder of trials it was unclear. In the majority of trials, participants were either not blind to their intervention condition, or it was unclear whether they were or not. Allocation concealment was also unclear in the majority of trials. Although all trials treated participants in an outpatient setting, the designs implemented in trials was diverse, which limits the generalisability of the results. Three trials indicated participants treated with antidepressant medication had lower relapse-recurrence rates (40.9%) compared to those treated with placebo (66.6%) during a relapse prevention phase (odds ratio (OR) 0.34; 95% confidence interval (CI) 0.18 to 0.64, P = 0.02). One trial that compared a combination of psychological therapy and medication to medication alone favoured a combination approach over medication alone, however this result did not reach statistical significance (OR 0.26; 95% CI 0.06 to 1.15). The majority of trials that involved antidepressant medication reported adverse events including suicide-related behaviours. However, there were not enough data to show which treatment approach results in the most favourable adverse event profile.

Authors' conclusions: Currently, there is little evidence to conclude which type of treatment approach is most effective in preventing relapse or recurrence of depressive episodes in children and adolescents. Limited trials found that antidepressant medication reduces the chance of relapse-recurrence in the future, however, there is considerable diversity in the design of trials, making it difficult to compare outcomes across studies. Some of the research involving psychological therapies is encouraging, however at present more trials with larger sample sizes need to be conducted in order to explore this treatment approach further.

PubMed Disclaimer

Conflict of interest statement

There are no declarations of interest for authors.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Medication versus placebo, Outcome 1 Number relapsed.
1.2
1.2. Analysis
Comparison 1 Medication versus placebo, Outcome 2 Suicide‐related behaviours.
1.3
1.3. Analysis
Comparison 1 Medication versus placebo, Outcome 3 Functioning (C‐GAS/GAF).
1.4
1.4. Analysis
Comparison 1 Medication versus placebo, Outcome 4 Depressive symptoms on clinician‐rated scale.
1.5
1.5. Analysis
Comparison 1 Medication versus placebo, Outcome 5 Drop‐outs.
2.1
2.1. Analysis
Comparison 2 COMB (med + psych) versus med, Outcome 1 Number relapsed.
2.2
2.2. Analysis
Comparison 2 COMB (med + psych) versus med, Outcome 2 Suicide‐related behaviours.
2.3
2.3. Analysis
Comparison 2 COMB (med + psych) versus med, Outcome 3 Functioning (C‐GAS).
2.4
2.4. Analysis
Comparison 2 COMB (med + psych) versus med, Outcome 4 Depressive symptoms on clinician‐rated scale.
2.5
2.5. Analysis
Comparison 2 COMB (med + psych) versus med, Outcome 5 Drop‐outs.

Update of

  • doi: 10.1002/14651858.CD007504

Similar articles

Cited by

References

References to studies included in this review

Cheung 2008 {published data only}
    1. Cheung A, Kusumakar V, Kutcher S, Dubo E, Garland J, Weiss M, et al. Maintenance study for adolescent depression. Journal of Child and Adolescent Psychopharmacology 2008;4:389‐94. - PubMed
Clarke 1999 {published data only}
    1. Clarke GN, Rohde P, Lewinsohn PM, Hops H, Seeley JR. Cognitive‐behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. Journal of the American Academy of Child & Adolescent Psychiatry 1999; Vol. 38, issue 3:272‐9. - PubMed
Emslie 1998 {published data only}
    1. Emslie GJ. Depression in children and adolescents [conference abstract]. 9th Congress of the Association of European Psychiatrists. Copenhagen, Denmark. Sept 20‐24, 1998.
    1. Emslie GJ, Heiligenstein JH, Hoog SL, Ernest DE, VanHooy B, Brown E, et al. Fluoxetine for maintenance of recovery from depression in children and adolescents: a placebo‐controlled, randomized clinical trial [Abstract No. NR736]. 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, LA. Arlington, VA: American Psychiatric Association, 2001.
    1. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depression and Anxiety 1998;7:32‐9. - PubMed
    1. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T. A double‐blind placebo controlled trial of fluoxetine in depressed children and adolescents [conference abstract]. Sixth World Congress of Biological Psychiatry, Nice, France. June 22‐27, 1997.
    1. Emslie GJ, Rush R, Weinberg WA, Kowatch WA, Hughes CW, Carmody T, et al. A double blind, randomized, placebo‐controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 1997;54(11):1031‐7. - PubMed
Emslie 2004 {published data only}
    1. Emslie GJ, Heiligenstein JH, Hoog SL, Wagner KD, Findling RL, McCracken JT, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double blind, placebo‐controlled study. Journal of the American Academy of Child & Adolescent Psychiatry 2004; Vol. 43, issue 11:1397‐405. - PubMed
    1. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo‐controlled, randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry 2002;41(10):1205‐15. - PubMed
Emslie 2008 {published data only}
    1. Emslie GJ, Kennard BD, Mayes TL, Nightingale‐Teresi J, Carmody T, Hughes CW, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. American Journal of Psychiatry 2008;165:459‐67. - PMC - PubMed
Kennard 2008 {published data only}
    1. Kennard BD, Emslie GJ, Mayes TL, Nightingale‐Teresi J, Nakonezny PA, Hughes JL, et al. Cognitive‐behavioral therapy to prevent relapse in paediatric responders to pharmacotherapy for major depressive disorder. Journal of the American Academy of Child & Adolescent Psychiatry 2008;47(12):1395‐404. - PMC - PubMed
Renaud 1998 {published data only}
    1. Birmaher B, Brent DA, Kolko D, Baugher M, Bridge J, Holder D, et al. Clinical outcomes after short‐term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry 2000;57:29‐36. - PubMed
    1. Brent DA, Birmaher B, Kolko D, Baugher M, Bridge J. Subsyndromal depression in adolescents after a brief psychotherapy trial: course and outcome. Journal of Affective Disorders 2001;63(1‐3):51‐8. - PubMed
    1. Brent DA, Holder D, Kolko D, Birmaher B, Baugher M, Roth C, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Archives of General Psychiatry 1997;54(9):877‐85. - PubMed
    1. Brent DA, Kolko DJ, Birmaher B, Baugher M, Bridge J. A clinical trial for adolescent depression: predictors of additional treatment in the acute and follow‐up phases of the trial. Journal of the American Academy of Child & Adolescent Psychiatry 1999;38(3):253‐70. - PubMed
    1. Kolko DJ, Brent DA, Baugher M, Bridge J, Birmaher B. Cognitive and family therapies for adolescent depression: treatment specificity, mediation, and moderation. Journal of Consulting and Clinical Psychology 2000;68(4):603‐14. - PubMed
TADS {published data only}
    1. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, et al. Relative cost‐effectiveness of treatments for adolescent depression: 36‐week results from the TADS randomized trial. American Academy of Child and Adolescent Psychiatry 2009;48(7):711‐20. - PubMed
    1. Kennard BD, Silva SG, Mayes TL, Hughes JL, Kratochvil CJ, Emslie GJ, et al. Assessment of safety and long‐term outcomes of initial treatment with placebo in TADS. American Journal of Psychiatry 2009;166(3):337‐44. - PMC - PubMed
    1. Kennard BD, Silva SG, Tonev S, Rohde P, Hughes JL, Vitiello B, et al. Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long‐term outcomes. Journal of the American Academy of Child & Adolescent Psychiatry 2009;48(2):186‐95. - PMC - PubMed
    1. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents with Depression Study (TADS): demographic and clinical characteristics. Journal of the American Academy of Child & Adolescent Psychiatry 2005;44(1):28‐40. - PubMed
    1. March J, Silva S, Vitiello B. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. Journal of the American Academy of Child & Adolescent Psychiatry 2006;45(12):1393‐403. - PubMed
TORDIA {published data only}
    1. Emslie GJ, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. American Journal of Psychiatry 2010;167(7):782‐91. - PMC - PubMed
    1. Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, et al. Long‐term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow‐up study of the TORDIA sample. Journal of Clinical Psychiatry 2011;72(3):388‐96. - PMC - PubMed

References to studies excluded from this review

ADAPT {published data only}
    1. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335(7611):142. - PMC - PubMed
    1. Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technology Assessment 2008;12(14):iii‐iv, ix‐60. - PubMed
Birmaher 1998 {published data only}
    1. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, Balach L, et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment‐resistant" major depression. Journal of the American Academy of Child & Adolescent Psychiatry 1998;37(5):527‐35. - PubMed
Birmaher 2000 {published data only}
    1. Birmaher B, Brent DA, Kolko D, Baugher M, Bridge J, Holder D, et al. Clinical outcome after short‐term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry 2000;57(1):29‐36. - PubMed
Eli 1986 {published data only}
    1. Eli Lilly. Fluoxetine: fluoxetine versus placebo in adolescent depressed patients [Trial 236]. Eli Lilly ‐ Clinical Study Register (http://www.lillytrials.com) 1986.
Eli 1995 {published data only}
    1. Eli Lilly. Fluoxetine versus placebo in the acute treatment of major depressive disorder in children and adolescents [Trial 375]. Eli Lilly ‐ Clinical Study Register (http://www.lillytrials.com) 1995.
Emslie 2009 {published data only}
    1. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris A. Escitalopram in the treatment of adolescent depression: a randomized placebo‐controlled multisite trial. Journal of the American Academy of Child & Adolescent Psychiatry 2009;48(7):721‐9. - PubMed
    1. Forest Laboratories. A double‐blind, fixed‐dose extension study of escitalopram in pediatric patients with major depressive disorder [SCT‐MD‐32/32A]. Forest Laboratories ‐ Clinical Study Register (http://www.forestclinicaltrials.com) 2007.
Franchini 2006 {published data only}
    1. Franchini L, Bongiorno F, Spagnolo C, Florita M, Santoro A, Dotoli D, et al. Psychoeducational group intervention in addition to antidepressant therapy as relapse preventive strategy in unipolar patients. Clinical Neuropsychiatry 2006; Vol. 3, issue 4:282‐5.
GlaxoSmithKline 1997 {published data only}
    1. GlaxoSmithKline. A multi‐center, double‐blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression ‐ acute phase (29060/329). GSK ‐ Clinical Study Register (http://www.gsk‐clinicalstudyregister.com) 1997.
    1. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry 2001;40(7):762‐72. - PubMed
GlaxoSmithKline 2001 {published data only}
    1. GlaxoSmithKline. A randomized, multi‐center, 8‐week, double‐blind, placebo‐controlled, flexible‐dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder (MDD). GSK ‐ Clinical Study Register (http://www.gsk‐clinicalstudyregister.com) 2001.
TADS(acute phase) {published data only}
    1. Jacobs RH, Silva SG, Reinecke MA, Curry JF, Ginsburg GS, Kratochvil CJ, et al. Dysfunctional attitudes scale perfectionism: a predictor and partial mediator of acute treatment outcome among clinically depressed adolescents. Journal of Clinical Child & Adolescent Psychology 2009;38(6):803‐13. - PMC - PubMed
    1. Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, et al. Remission and residual symptoms after short‐term treatment in the Treatment of Adolescents with Depression Study (TADS). Journal of the American Academy of Child & Adolescent Psychiatry 2006;45(12):1404‐11. - PubMed
    1. Kratochvil C, Emslie G, Silva S, McNulty S, Walkup J, Curry J, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). Journal of the American Academy of Child & Adolescent Psychiatry 2006;45(12):1412‐8. - PubMed
    1. Lewis CC, Simons AD, Silva SG, Rohde P, Small DM, Murakami JL, et al. The role of readiness to change in response to treatment of adolescent depression. Journal of Consulting and Clinical Psychology 2009;77(3):422‐8. - PMC - PubMed

References to studies awaiting assessment

Oleichik 1998 {published data only}
    1. Oleichik IV, Artiouch VV. The treatment of cognitive symptoms of adolescent endogenous depressive disorders. 11th European College of Neuropsychopharmacology Congress, Paris, France. 31st October ‐ 4th November 1998.

References to ongoing studies

Goodyer 2011 {published data only}
    1. Goodyer IM, Tsancheva S, Byford S, Dubicka B, Hill J, Kelvin R, et al. Improving mood with psychoanalytic and cognitive therapies (IMPACT): a pragmatic effectiveness superiority trial to investigate whether specialised psychological treatment reduces the risk for relapse in adolescents with moderate to severe unipolar depression: study protocol for a randomised controlled trial. Trials 2011;12:175. - PMC - PubMed
NCT00612313 {unpublished data only}
    1. Emslie GJ. Pediatric MDD: sequential treatment with fluoxetine and relapse prevention. ClinicalTrials.gov (http://www.clinicaltrials.gov) 2008; Vol. http://clinicaltrials.gov/show/NCT00612313 (accessed 23 November 2011).

Additional references

AACAP 2007
    1. American Academy of Child, Adolescent Psychiatry (AACAP). Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child & Adolescent Psychiatry 2007;46(11):1503‐26. - PubMed
Allen 2007
    1. Allen NB, Hetrick SE, Simmons JG, Hickie IB. Early intervention in depressive disorders in young people: the opportunity and the (lack of) evidence. Medical Journal of Australia 2007;187(7):s15‐7. - PubMed
Alvarez‐Jimenez 2011
    1. Alvarez‐Jimenez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta‐analysis of psychosocial and pharmacological trials in first‐episode psychosis. Schizophrenia Bulletin 2011;37(3):619‐30. - PMC - PubMed
APA 2000
    1. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV‐TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
Beck 1969
    1. Beck AT, Ward CH, Mendelssohn MJ, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561‐71. - PubMed
Belsher 1988
    1. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychological Bulletin 1988;104(1):84‐96. - PubMed
Berndt 2000
    1. Berndt ER, Koran LM, Finkelstein SN, Gelenberg AJ, Kornstein SG, Miller IM, et al. Lost human capital from early‐onset chronic depression. American Journal Psychiatry 2000;157(6):940‐7. - PubMed
Birmaher 1996
    1. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE. Childhood and adolescent depression: a review of the past 10 years: part 1. Journal of the American Academy of Child & Adolescent Psychiatry 1996;35(11):1427‐39. - PubMed
Bridge 2007
    1. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in paediatric antidepressant treatment a meta‐analysis of randomized controlled trials. JAMA 2007;297(15):1683‐96. - PubMed
Cheung 2007
    1. Zuckerbrot RA, Cheung AH, Zuckerbrot RA, Jensen PS, Ghalib K, Laraque D, et al. Guidelines for adolescent depression in primary care (GLAD‐PC): II treatment and ongoing management. Pediatrics 2007;120:e1313‐26. - PubMed
Churchill 2010
    1. Churchill R, Moore THM, Davies P, Caldwell D, Jones H, Lewis G, et al. Mindfulness‐based ’third wave’ cognitive and behavioural therapies versus treatment as usual for depression. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD008705] - DOI - PMC - PubMed
Clarke 1990
    1. Clarke GN, Lewinsohn PM, Hops H, Seeley JR. Instructors Manual for the Adolescent Coping With Depression Course. Eugene, OR: Castalia Press, 1990.
Clarke 2005
    1. Clarke G, Debar L, Lynch F, Powell J, Gale J, O'Connor E, et al. A randomized effectiveness trial of brief cognitive‐behavioral therapy for depressed adolescents receiving antidepressant medication. Journal of the American Academy of Child & Adolescent Psychiatry 2005;44:888‐98. - PubMed
Costello 2006
    1. Costello JE, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression?. Journal of Child Psychology and Psychiatry 2006;47(12):1263–71. - PubMed
Cox 2012
    1. Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database of Systematic Reviews 2012. - PubMed
Crown 2002
    1. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment‐resistant depression on health care utilization and costs. Journal of Clinical Psychiatry 2002;63(11):963‐71. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Dobson 2008
    1. Dobson KS, Dimidjian S, Kohlenberg RJ, Rizvi SL, Dunner DL, Jacobson NS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. Journal of Consulting and Clinical Psychology 2008;76(3):468‐77. - PMC - PubMed
Fava 1998
    1. Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA. Six‐year outcome for cognitive behavioral treatment of residual symptoms for major depression. American Journal of Psychiatry 1998;155:1443‐5. - PubMed
Fisher 2010
    1. Fisher CA, Hetrick SE, Rushford N. Family therapy for anorexia nervosa. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD004780.pub2] - DOI - PubMed
Frank 1991
    1. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 1991;48:851‐5. - PubMed
Geddes 2003
    1. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361(9358):653‐61. - PubMed
Goodyer 2007
    1. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335(7611):142. - PMC - PubMed
Hamilton 1960
    1. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960;23:56‐62. - PMC - PubMed
Harrington 1990
    1. Harrington R, Fudge H, Rutter M, Pickles A, Hill J. Adult outcomes of childhood and adolescent depression. 1. Psychiatric status. Archives of General Psychiatry 1990;47(5):465‐73. - PubMed
Hazell 2002
    1. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002317] - DOI - PubMed
Healy 1997
    1. Healy D. The Anti‐Depressant Era. Massachusetts: Harvard University Press, 1997.
Hensley 2004
    1. Hensley PL, Nadiga D, Uhlenhuth EH. Long‐term effectiveness of cognitive therapy in major depressive disorder. Depression and Anxiety 2004;20(1):1‐7. - PubMed
Hetrick 2007
    1. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004851.pub2] - DOI - PubMed
Hetrick 2008
    1. Hetrick SE, Parker AG, Purcell R, Hickie I, Yung AR, McGorry PD. Early identification and intervention in depressive disorders: toward a clinical staging model. Journal of Psychotherapy and Psychosomatics 2008;77(5):263‐70. - PubMed
Hetrick 2012
    1. Hetrick SE, McKenzie JE, Cox GR, Simmons M, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2012. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Higgins 2008a
    1. Higgins JPT, Altman DG, On behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Hoffman 2008
    1. Hofmann SG, Asmundson GJG. Acceptance and mindfulness‐based therapy: new wave or old hat?. Clinical Psychology Review 2008;28(1):1‐16. - PubMed
Jaffee 2002
    1. Jaffee SR, Moffitt TE, Caspi A, Fombonne E, Poulton R, Martin J. Differences in early childhood risk factors for juvenile‐onset and adult‐onset depression. Archives of General Psychiatry 2002;59(3):215‐22. - PubMed
Jarrett 2001
    1. Jarrett RB, Kraft D, Doyle J, Foster BM, Eaves GG, Silver PC. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Archives of General Psychiatry 2001;58:381‐8. - PMC - PubMed
Keller 1984
    1. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long‐term outcomes of episodes of major depression: clinical and public health significance. JAMA 1984;252:788‐92. - PubMed
Keller 2005
    1. Keller MB, Ruwe FKL, Janssens CJJG, Sitsen JMA, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. Journal of Clinical Pharmacology 2005;25(1):79‐84. - PubMed
Kendler 2000
    1. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. American Journal of Psychiatry 2000;157(8):1243‐51. - PubMed
Kennard 2006
    1. Kennard BD, Emslie GJ, Mayes TL, Hughes JL. Relapse and recurrence in paediatric depression. Child and Adolescent Psychiatric Clinics of North America 2006;15:1057‐79. - PubMed
Kennedy 2003
    1. Kennedy N, Abbott R, Paykel ES. Remission and recurrence of depression in the maintenance era: long‐term outcome in a Cambridge cohort. Psychological Medicine 2003;33:827‐38. - PubMed
Kessing 2004
    1. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994‐1999. British Journal of Psychiatry 2004;185:372‐7. - PubMed
Kessler 2005
    1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age‐of‐onset distributions of DSM‐IV disorders in the National Comorbidity Survey replication. Archives of General Psychiatry 2005;62:593‐602. - PubMed
Kroll 1996
    1. Kroll L, Harrington R, Jayson D. Pilot study of continuation cognitive‐behavioral therapy for major depression in adolescent psychiatric patients. Journal of the American Academy of Child & Adolescent Psychiatry 1996;35(9):1156‐61. - PubMed
Lau 2004
    1. Lau MA, Segal ZV, Williams JM. Teasdale's differential activation hypothesis: implications for mechanisms of depressive relapse and suicidal behaviour. Behavior Research and Therapy 2004;42(9):1001‐17. - PubMed
Lewinsohn 1999
    1. Lewinsohn PM, Allen NB, Seeley JR, Gotlib IH. First onset versus recurrence of depression: differential processes of psychosocial risk. Journal of Abnormal Psychology 1999;108:483‐9. - PubMed
Ma 2004
    1. Ma SH, Teasdale JD. Mindfulness‐based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. Journal of Consulting and Clinical Psychology 2004;72(1):31‐40. - PubMed
March 2004
    1. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al (Treatment for Adolescents with Depression Team). Fluoxetine, cognitive‐behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292(7):807‐20. - PubMed
Marlatt & Gordon 1985
    1. Marlatt GA, Gordon JR. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviours. New York: Guildford, 1985.
Martell 2010
    1. Martell CR, Dimidjian S, Herman‐Dunn R. Behavioral Activation for Depression: A Clinician’s Guide. New York: Guilford, 2010.
McDermott 2010
    1. McDermott B, Baigent M, Chanen A, Fraser L, Graetz B, Hayman N et al. beyondblue Expert Working Committee. Clinical practice guidelines: depression in adolescents and young adults. beyondblue: the National Depression Initiative: Melbourne 2010.
McGorry 2006
    1. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry 2006;40:616‐22. - PubMed
Melvin 2006
    1. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit EA. Comparison of cognitive‐behavioral therapy, sertraline, and their combination for adolescent depression. Journal of the American Academy of Child & Adolescent Psychiatry 2006;45:1151‐61. - PubMed
Merry 2011
    1. Merry SN, Hetrick SE, Cox GR, Brudevold‐Iversen T, Bir JJ, McDowell H. Psychological and educational interventions for preventing depression in children and adolescents. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003380.pub3] - DOI - PubMed
NICE 2005
    1. National Institute for Health and Clinical Excellence (NICE). Depression in children and young people: identification and management in primary, community and secondary care. The British Psychological Society: Leicester, UK 2005. - PubMed
Nobile 2003
    1. Nobile M, Cataldo GM, Marino C, Molteni M. Diagnosis and treatment of dysthymia in children and adolescents. CNS Drugs 2003;17(13):927‐46. - PubMed
Olver 2001
    1. Olver JS, Burrows GD, Norman TR. Third‐generation antidepressants: do they offer advantages over the SSRIs?. CNS Drugs 2001;15(12):941‐54. - PubMed
Post 1992
    1. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. American Journal of Psychiatry 1992;149(8):999‐1010. - PubMed
Poznanski 1996
    1. Poznanski EO, Mokros HB. Children's Depressions Rating Scale, Revised (CDRS‐R) Manual. Los Angeles: Western Psychological Services, 1996.
Rapaport 2004
    1. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. Journal of Clinical Psychopharmacology 2004;65(1):44‐9. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Reynolds 1987
    1. Reynolds WM. Suicidal Ideation Questionnaire‐Junior.. Odessa, FL: Psychological Assessment Resources, 1987.
Rush 1998
    1. Rush AJ, Koran LM, Keller MB, et al. The treatment of chronicdepression, part 1: study design and rationale for evaluating thecomparative efficacy of sertraline and imipramine as acute, crossover,continuation, and maintenance phase therapies. Journal of Clinical Psychiatry 1998;59:589‐97. - PubMed
Rutter 1995
    1. Rutter M, Smith DJ. Psychosocial Disorders in Young People: Time Trends and Their Causes. Chichester, England: John Wiley & Sons, 1995.
Segal 2010
    1. Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness‐based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Archives of General Psychiatry 2010;67(12):1256‐64. - PMC - PubMed
Shaffer 1983
    1. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children's global assessment scale (CGAS). Archive of General Psychiatry 1983;40(11):1228‐31. - PubMed
Simon 2004
    1. Simon JS, Aguiar LM, Kunz NR, Lei D. Extended‐release venlafaxine in relapse prevention for patients with major depressive disorder. Journal of Psychiatric Research 2004;38(3):249‐57. - PubMed
Teasdale 2000
    1. Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness‐based cognitive therapy. Journal of Consulting and Clinical Psychology 2000;68(4):615‐23. - PubMed
Thompson 2003
    1. Thompson KN, Conus PO, Ward JL, Phillips LJ, Koutsogiannis J, Leicester S, et al. The initial prodrome to bipolar affective disorder: prospective case studies. Journal of Affective Disorders 2003;77(1):79‐85. - PubMed
Vallis 1986
    1. Vallis MT, Shaw, BF, Dobson KS. The Cognitive Therapy Scale: Psychometric properties.. Journal of Consulting and Clinical Psychology 1986;54(3):381‐85. - PubMed
van Praag 1987
    1. Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A, et al. Denosologization of biological psychiatry or the specificity of 5‐HT disturbances in psychiatric disorders. Journal of Affective Disorders 1987;13:1‐8. - PubMed
Vittengl 2007
    1. Vittengl JR, Clark LA, Dunn TW, Jarrett RB. Reducing relapse and recurrence in unipolar depression: a comparative meta‐analysis of cognitive‐behavioral therapy's effects. Journal of Consulting and Clinical Psychology 2007;75(3):475‐88. - PMC - PubMed
Wantanabe 2007
    1. Watanabe N, Hunot V, Omori IM, Churchill R, Furukawa TA. Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatrica Scandinavica 2007;116:84‐95. - PubMed
Weissman 2007
    1. Weissman MM, Markowitz JC, Klerman GL. Clinician’s Quick Guide to Interpersonal Psychotherapy. New York: Oxford University Press, 2007.
Weisz 2006
    1. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta‐analysis. Psychological Bulletin 2006;132:132‐49. - PMC - PubMed
WHO 2007
    1. World Health Organization. International Classification of Diseases and Related Health Problems 10th Revision (ICD‐10) (accessible online: http://apps.who.int/classifications/apps/icd/icd10online/). Geneva: WHO, 2007.
Yung 2003
    1. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12‐month follow up of a high‐risk ("prodromal") group. Schizophrenia Research 2003;60(1):21‐32. - PubMed

Publication types

Substances